Contrasting Aptevo Therapeutics (NASDAQ:APVO) & CSL (OTCMKTS:CSLLY)

CSL (OTCMKTS:CSLLY) and Aptevo Therapeutics (NASDAQ:APVO) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations.

Profitability

This table compares CSL and Aptevo Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CSL	N/A	N/A	N/A
Aptevo Therapeutics	N/A	-488.93%	-152.51%

Valuation and Earnings

This table compares CSL and Aptevo Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CSL	$14.80 billion	5.19	$2.64 billion	N/A	N/A
Aptevo Therapeutics	$3.11 million	1.13	-$24.13 million	N/A	N/A

CSL has higher revenue and earnings than Aptevo Therapeutics.

Analyst Recommendations

This is a breakdown of current recommendations for CSL and Aptevo Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CSL	0	0	0	2	4.00
Aptevo Therapeutics	0	0	1	0	3.00

Aptevo Therapeutics has a consensus price target of $10,952.00, suggesting a potential upside of 454,339.83%. Given Aptevo Therapeutics’ higher possible upside, analysts plainly believe Aptevo Therapeutics is more favorable than CSL.

Insider & Institutional Ownership

0.0% of CSL shares are held by institutional investors. Comparatively, 8.1% of Aptevo Therapeutics shares are held by institutional investors. 0.1% of Aptevo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Risk and Volatility

CSL has a beta of 0.78, indicating that its share price is 22% less volatile than the S&P 500. Comparatively, Aptevo Therapeutics has a beta of 5.24, indicating that its share price is 424% more volatile than the S&P 500.

Summary

CSL beats Aptevo Therapeutics on 7 of the 12 factors compared between the two stocks.

About CSL

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.

About Aptevo Therapeutics

Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. The company's lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia. It is also developing ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for NSCLC, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate for multiple solid tumors; APVO442, a novel bispecific candidate based on the ADAPTIR-FLEX platform technology for multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate for prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.